Company Profile
Daiichi Sankyo
— A pharmaceutical company aiming for a global top-five oncology position on the strength of its proprietary DXd ADC platform
In the topic of drug discovery and DDS, the first three co-name came out,We created a system to carry drugs called antibody drug complex (ADC) in-house, and developed it as a main product.Home Earnings of 5 items referred to as DXd ADC in FY2025 (fiscal year ending March 31, 2026)¥9,253 billionContact Us On the other hand, as a result of reviewing the ADC demand forecast,Compensation for loss to manufacturing contractors (CMO) and cancellation of ADC-related investments at Odawara PlantIn this article, the size of the company is concise,What to do with ADC technology, where to go and what to do nextFilter by
- In 30 seconds, the first three cooperatives and the standing position in drug discovery and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Size of the company (the entire company is concise)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Standing position in drug discovery and DDS with the first three colonies in 30 seconds
(ADC)From search to approval and sales
USA MerckThe manufacturing and supply of ADCs is carried out by Dai-ichi Sankyo.
Businesses related to drug discovery and DDS are largeBiotech and Contract Development Manufacturing (CDMO/CRO)3 types.Pharmaceutical CompanyHowever, the center is not a specific diseaseDXd ADCHome FactsHome ADC is a drug that connects a strong drug (payload) through a linker to antibodies that bind to a mark (antigen) on the surface of cancer cells. A representative example of DDS (drug-assisted system) that delivers the drug to cancer cells by “carrying” antibody. The company uses the same payload and drug linker by simply changing the antibody,5 items such as Enharts (anti-HER2), Datroway (anti-TROP2)We have developed. “BGT (Breakthrough。rating Technology) = core technology that produces multiple new drugs”
This article explains the company's technical strategy and business.Not medical adviceHome There is no intention to recommend the use of certain drugs or compare the effects of other drugs. The results of clinical trials are based on the comparison of the numbers published by the company and at the time of evaluation. Please contact your doctor for the treatment.
2. Logo and company name
Dai-ichi Sankyo Chemical Co., Ltd. is a trademark of the company. In this article, we do not reproduce the generated image,
Images obtained from the official websiteHome img/daiichi_sankyo_logo.png Contact Us
Notes: Corporate name is "Daiichi Sankyo Co., Ltd." in English Daiichi Sankyo Company, LimitedHome "U.S. Merck" partner Merck & Co., Inc., Rahway, NJ, USA(Merck KGaA) Since the first three co-owner is also written as "U.S. Merck" in the document, this article also follows it.
Official Site:https://www.daiichisankyo.co.jp/3. Where is this company in the world of drug discovery and DDS?
This company has three elements of "antibody + linker + payload" handled by the technical commentary "antibody medicine and ADC" in this series. According to a researcher’s interview on the company’s recruitment site, antibody know-how from the three-complex era, and the compound DX-DX1 based on payload is the research result of the first pharmaceutical era, and it is explained that the research results of both companies were overlapping by management integration. Facts。
4. Scope of the company (the entire company is concise)
The scale of the entire company stays in one table FactsHome The first threeRevised FY2025 Financial Results on July 31, 2026The operating income and this year's operating income for FY2025 are revised. Sales revenue and R&D expenses are not subject to correction.
| Index (Millions of yen) | FY2024 | FY2025 | FY2026 Forecast (Announced July) |
|---|---|---|---|
| Sales revenue | 18,863 | 21,230 | 23,400 |
| R&D expenses ( ing overtime costs) | 4,329 | 4,621 | 5,000(New definition) |
| Operating income | 3,319 | 2,580(After correction) | 3,200 |
| Profit attributable to parent company | 2,958 | 2,797 (After correction) | ― |
| Facility investment | ― | 1,354 | 2,000 |
| Number of employees | ― | 20,000 people | End of June 2026 |
Dai-ichi Sankyo has changed the definition of "core operating profit" from FY2026. Research and development costs are based on the new definition (core costs outside the core) for FY2025 and FY2026.Strictly not the same thingHome Research and development costs for FY2025 under the new definitions are disclosed to ¥4,616 billion FactsHome The operating income for FY2025 fell from the previous、 year.Expenses for overtime costs of ¥15.3 billion in response to the revision of ADC supply planChapter 6.
5. Drug discovery and DDS resources
The first three cooperatives do not disclose the breakdown of R&D expenses separately, DXd ADCThe company itself explains (The reason for the increase in R&D expenses in FY2025 is "increasing R&D investment in 5DXd ADCs") Facts。
| Resource Types | ||
|---|---|---|
| People (Research Centers and Personnel) | Number of employees20,000 people(As of March 31, 2014) 9,531 Japan, 4,098 North America, 3,468 European, and 3,074 others) As a roadmap for research systems for FY2030, the extension of Shinagawa’s research functions,Boston Munich San DiegoOpened the Smart Research Lab in San Diego.Non-dis sure of the number of people engaged in drug discovery research and ADC | Facts |
| Gold (R&D expenses) | FY20254,621 billion yen(about 21.8% of revenue). FY2026 forecast 50 billion yen R&D investment in increased 5DXd ADCs | Facts |
| Gold (Manufacturing Equipment) | Expanded ADC production line at 3 domestic plants in 2017 (initial investment)Approx. 1.5 billion yen3 times or more of the production scale of biopharmaceu s by 2021. Capital investment in FY2025 was JPY1,424 billion and JPY2026.Non-discretionary investments limited to ADC equipmentHome May 2026Discretionary investment of ADC related facilities at Odawara Plant | Facts |
| Manufacturing outsour | ADC commercial productionCMOContact Us We promise to secure minimum purchase obligations and dedicated lines in long-term contracts, reviewing demand forecastsLoss compensationis generated.CMO company name is not disclosed | Facts |
| Five-year investment | 2026-2030 growth investment (R&D, capital investment, strategic investment)About 2.9 trillion yenbuting policy | Facts |
| External investment, acquisition and introduction | From US MerckMK-6070 (Three-dimensional T-cell enhancer targeting DLL3)Co-development and sales rights are acquired at the time of contract for $ 17,000 million (August 2024). Large acquisitions are not included in the materials | Facts |
| External license (lic -out) | Research and development of 1 in our own laboratory, which was born in our own laboratory, is introduced to other companies and is expected to receive Milestone Royalty.The company name is not included in the description. | Facts |
| University/Research Organization/Public Fund | Public offering program for drug discovery joint research with AmiTaNeDSOperation. Development of mRNA vac) (dithyrona) is supported by Japan Medical Research and Development Organization (AMED) and Ministry of Health, Labour and Welfare | Facts |
The first three co-developed and sold by the end of March 2026 Total from AstraZeneca ¥6,851 billion, Total from US Merck ¥6,978 billionContact Us T payment, development milestone, sales milestone etc. FactsHome In total, it is about 18.3 billion yen, and about 3 years of research and development costs for FY2025. The calculation of this paperHome On the other hand, the benefit of the region except Japan is with partnersIn FY2025, we paid 3,056 billion yen as "Profit Share of DXd ADC products". Facts。
6. Past Initiatives
| Time | Home | |
|---|---|---|
| Before business integration | We developed DX-DX1 of DXtoxin in the first pharmaceutical era. DE-310, combined with sugar chain polymer, has been disclosed. | ADC Payload (DXd) Calculation |
| April 2017 | Announ) capital investment (initial investment about 1.5 billion yen) to increase ADC production line in three domestic factories | At the time, we had two clinical and four preclinical stages. |
| March 2019 | Global Alliance between AstraZeneca and Enharts (DS-8201)Home Up to $69 billion | Fold profits and costs worldwide except Japan. Manufacturing and supply |
| 20 December 2019 | The U.S. FDA approved enemas (HER2-positive non-resectable and metastatic breast cancer with two or more lines of anti-HER2 therapy). | First approval as DXd ADC. Quick approval framework in the US |
| March 2020 | Approval of Enhart in Japan (Conditional Early Approval System) | Interstitial lung disease (ILD) is described in the "Warning" field of the attachment |
| July 2020 | Global Alliance between AstraZeneca and Datroway (DS-1062)Home Up to $60 billion | The second ADC partnership with AstraZeneca |
| August 2023 | Approval of mRNA vac "Daityrona" in Japan (additional immunity) | The first mRNA vac in Japan. LNP technology can be used to distribute in refrigeration (2 to 8 °C) |
| October 2023 | Global Partnership between US Merk and HER3-DXd, I-DXd, R-DXdHome Up to $220 billion | DXd ADC Manufacturing and supply |
| August 2024 | Added MK-6070 (T-cell engager) to contract with Merck, USA. | Other modalities besides ADC. Plans to evaluate combination with I-DXd. |
| December 2024 | The world's first DATROWAY approval (HR-positive and HER2-negative milk cancer) | DXd ADC |
| January 2025 | U.S. FDA approves Datroway (adaptation of the same milk cancer) | Second DXd ADC in USA |
| May 2025 | EGFR mutated non-small cell lung cancer targeting HER3-DXd US approval applications | 5 events that show that everything is not in good condition |
| October to November 2025 | ADC DS3610, which payloads NMD in tor DS5361 and STING agonistTargeted Protein Decomposition Inhibitor DS9051 | ADC's next technical base candidates for clinical phase |
| March 2026 | HER2-positive multiple solids in Japan and partial change approval | Adaptation for "HER2 positive" regardless of organ |
| May 8, 2026 | Review of ADC supply planAnnouncement of compensation for losses to CMO and dissolution of ADC-related investments at Odawara Plant | Chapter 11: Manufacturing plans with 'no risk adjustment' to predict demand (Chapter 11) |
| May 2026 | Enharts approves preoperative therapy (DESTINY-Breast11) and postoperative therapy (DESTINY-Breast05) for HER2-positive early milk cancer in the United States. Datroway Approved Triple Negative Dairy Cancer Primary Treatment (TROPION-Breast02) | Adaptation from metastatic cancer to early cancer has spread |
| June 2026 | Enharts approves HER2-positive solid cancer in Europe | Three poles of Japan-U.S. and Europe |
Major clinical trials based on approval
| Test (NCT number) | Phase | Main evaluation items | Results published by the Company (at the time of comparison and evaluation) |
|---|---|---|---|
| DESTINY-Breast11（NCT05113251） | Phase 3 High-risk HER2-positive early milk cancer preoperative therapy | pathological complete response (pCR) rate | 11.2 points improvement of pCR rate compared to ddAC-THP therapy group (95% confidence interval 4.0–18.3). Data cut off on March 12, 2025 |
| DESTINY-Breast05（NCT04622319） | Phase 3 Postoperative therapy of HER2-positive lactose lesion of invasion after preoperative therapy | Lifetime without invasive disease (IDFS) | The company announced that it showed statistically significant IDFS improvements compared to T-DM1 (Trussuzumab Mt.).Numbers are not listed in the documents confirmed in this article |
| TROPION-Breast02（NCT05374512） | Phase 3 Primary treatment of PD-1/PD-L1 in tor and static metastatic triple negative milk cancer | Unexpensive survival (PFS), full survival (OS) | PFS Central: 5.3 months, OS Central: 35.0 months, Response rate: 62.5% vs. 29.3%.At the time of analysis (data cutoff date) is not specified in the document confirmed in this article |
| IDeate-Lung01（NCT05280470） | Phase 2 Advanced Small Cell Lung Cancer | Objective response efficiency (ORR) | I-DXd ORR 48.2% confirmed by all participants of 12mg/kg.Single-group trial without comparison contrastHome Data cutoffs announced on March 3, 2025 at WCLC 2025 |
I-DXd receives US approval application for this data, and the end date of the examination isOctober 10, 2026Home Not determined at the moment whether approved Undetermined / Future。
7. Future plans
Operating income: ¥60 billion or moreMedium-Term Management Plan (FY2026-2030)
(FY2018)FY2025: 9,540 billion yen
Global Top 5Deliver to over 7 million patients per year
Next BGTIdentify core technology following DXd ADC
| Candidates of the following technical foundations (BGT candidates and new ADCs) | Home | Stages and Periods indicated by the Company |
|---|---|---|
| Antibody modified ADC | ADC | First Phase Test Plan for FY2027 |
| Immunotherapy (IO) Payload | ADC | DS3610 |
| New Cell Injury Payload | ADC (to overcome resistance to DXd ADC) | First Phase Test Plan for FY2027 |
| Multi-Syphic Antibody | Antibody (T-cell engager, etc.) | DS2243 |
| Targeted Protein Decomposition Induction (TPD) | Low)s (linked with drug discovery chemistry and AI drug discovery) | DS9051 |
| siRNA | Nucleic acid (New chemical modifier + LNP / ADC) | First Phase Test Plan for FY2026 |
| CD25 ADC(DS1025) | ADC (Remove controllable T cells) | First human dose test scheduled to start in the first half of FY2026 |
We changed our policy in May 2026. In the past, it was a form of "assign production volume with CMO" but in the futureOur company is responsible for process development and commercial production, and uses CMO as a foundation for commercial productionOur company + CMO flexible collaboration system FactsHome In the above-mentioned aspects, we have expanded the research functions of AI-based DX design and research digitization (Research DX) and Shinagawa.
Both of the following are not listed in the primary material that has been confirmed in this article Undetermined / Future。
ADC related equipmentInvestmentHomeProduction capacityContactCompany nameHomeMinimum purchase dutyResearch and Development CostModality/siRNA and TPDTarget disease(DS9051)/ I-DXd・R-DXdApproval periodHome No news-based sales forecasts such as “First Three Cos are USD X billion per year”. "DXd ADC has more than 3 trillion peak sales potential"Company Profile
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| The next core technology isADC Extension Line TopContact Us | Three of the six BGT candidates (antibody modified ADC, IO payload, and new cell injured payload) presented by the medium document are ADC. New anti-CD25 ADC (DS1025) released in July 2026. Reusable antibody linker payload umulation | |
| from a form that breaks profits through alliances,Percentage of independent development and salesMore | Nakameguro has established a global commercialization organization in FY2027 with the establishment of its own independent capability according to the progress of the。. Profit Share for FY2025 JPY3,056 | |
| Other than cancerResearch and concentrationClose | Transfer of shares of Daiichi Sankyo Healthcare to HDHD (¥2,465 billion) and reorganization costs of the European Specialty Business. Nakamega explains management resources as 'concentrating on innovative pharmaceutical business'. | Facts |
| nucleic acid (siRNA) and TPDNext Next to ADC | Both phase 1 or before starting. The company is positioned as investment for sustainable growth since the mid-2030s | |
| mRNA・LNP technologyFrom in ious disease vac to siRNA secretion | The explanation of siRNA is "fusion of the technology of LNP and ADC" and explains that Daityrona established its own LNP technology. |
In May 2026, as a problem to overcome for FY2030Lixiana's patent expires, the end of the sale milestone receipt of enemas, decreased revenue for ironic business.Home FY2035Endorsement of patentHome FactsHome CompanyEnharts, the head of earning now, has been patented in the 2030sWe have a plan based on what we do. By the core of the sixth term, whether you can create a new BGT that follows the DXd ADC business, Because half of the candidate is an improved type of ADC."Use the assets of antibodies, linkers, payloads, and manufacturing built with ADC again in the next generation" strategyread Undetermined / FutureHome However, there are many unrelated candidates such as siRNA and TPD, and it is believed that the dispersion from one ADC is aiming at the same time.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Products & Technologies | modalities/targets | Contact |
|---|---|---|
| Enharts (Trussuzumab Delxekan) | ADC／HER2 | Approved. Approved in more than 95 countries and regions, with more than 10 indications in the cancer area. Global product sales for FY2025 ¥6,984 billion (company disclosure) AstraZeneca (including the region) |
| Datoloway (Datopotamab Derkstekan) | ADC／TROP2 | Approved (Japan, USA, etc.) Global product sales for FY2025: 47 billion yen |
| I-DXd | ADC／B7-H3 | Under development (approved application acceptance in the United States, under review) |
| R-DXd | ADC／CDH6 | Developed (second phase, etc.). Ovarian cancer in the United States |
| HER3-DXd | ADC／HER3 | 3rd phase U.S. application for lung cancer was withdrawn in May 2025 |
| Dytyrona | mRNA vac) | Approved in Japan (August 2023) |
| Van Frita, Esalmia | Low | Approved. Van Frita approved in China in June 2026 |
| DXd ADC design elements | Description of company materials (2017 technical description) |
|---|---|
| Payload | Original DXd (exatecan derivative). Inhibition of DNA Topoisomerase I. IC50 is 0.31μM, stronger than the active metabolite SN38 (2.78μM) |
| Linker | A drug linker containing Tetrapeptide (Gly-Gly-Phe-Gly), cut by s. Designed to release drugs in blood and in cancer cells |
| Binding Style | AntibodyChain cysteine residueOne of the drug linkers with oestrogen binding |
| Drug antibody ratio ( ) | per antibody7 to 8 piecesHome Approx. double the previous generation of ADC (3.5 to 4) |
| Other features | "Bi effect" where the released drug acts on the surrounding cells, fast disappearance from the blood of the free drug (as a result of non-clinical) |
In ADC, the more effective it increases the drug that can be put in one antibody, but because the drug linker is highly hydrophobic, If you put too much antibody, it will become agglomerated and disappear immediately from the bloodThere is a wall. In 2017, the structure of a short spacer between antibodies and drugs is compared to seven FactsHome No spacer is a cohesive26%2 to 20% of carbon chains, while 2.5 to 3.8 Spacer with ether binding (-NH-CH)2OCH2-C(=O)-0.6% aggregate in 7.7Achieve DXd ADC different is not only the strength of payloadResults of polymer chemistry and process chemistry called 'A linker design that does not coagulate even with eight hydrophobic drugs'Comment
In terms of production, antibody (culture and refining of biopharmaceu s) and drug linker (multi-stage organic )Two different processes at the endrequired It is also necessary to contain high-activity drugs. The CMO problem in 2026 is backed by the difficulty of manufacturing that pushes such a dedicated line in a long-term contract. Also established in DichironaLNPThe company explains the technology of siRNA, and the technology of lipid design and formulation is expected to be effective even in the next generation. Undetermined / FutureHome Please refer to the technical commentary of this series "lipid nanoparticles" and "nucleic acid medicine".
11. Risks that this company has
| Risks | ||
|---|---|---|
| Focus on ADC | DXd ADC 5 items account for ¥9,253 billion (approx. 43.6%) out of ¥2 trillion and ¥30 trillion in revenue for FY2025 | The calculation of this paper |
| Minimum purchase obligation | The company expressed that the difference between the new supply plan and the minimum purchase obligation to CMO occurs.Long-term differences are not drawn because of high uncertaintythe possibility of additional draws in the future | Facts |
| Patent Expiration | The company itself has a patent for Lixiana, which will expire in 2030, and the patent for Enharts will expire in 2035 is a challenge to overcome. | Facts |
| Half profit with partners | 。ing Japan, the benefit of the region is folded with partners. The company explains that the sale of Em Hearts Milestone also goes to the end | Facts |
| Uncertainty of development | HER3-DXd took the U.S. application for lung cancer seriously. I-DXd's U.S. examination results are not confirmed as expected in October 2026 | Facts |
| Safety | Enharts and Datroway are listed in the "Warning" section of the Japanese attachment. The more the indication spreads to early cancer, the more the weight of safety management | Facts |
| Correction of financial reporting | Revised the 2025 financial results in July 2026 (reduction of ¥290 billion in sales and general management costs). The details of the revision are not written in the documents confirmed in this article | Facts |
| The next technical foundation | Most BGT candidates have not decided which will contribute to the business by 2030 before the first phase or start |
12. Glossary
- ADC
- Drugs that combine strong drugs (payloads) through a linker to antibodies. Bringing antibody to cancer cells
- Payload
- ADC DXd is a compound that in ts DNA topoisomerase I.
- Linker
- Chemical structure that connects antibody and drugs. In the blood, it is necessary to remove the cancer cells.
- (Drug antibody ratio)
- Number of drugs combined per antibody. The more powerful it is, but it is easier to get agglomeration and blood loss.
- LNP
- Particulates made of lipid that are wrapped in mRNA and siRNA and delivered into cells.
- BGT
- Breakthroughratingrating Technology Our proprietary core technology that enables multiple new drugs in the words used by Dai-ichi Sankyo.
- CMO
- Contract Manufacturing Organization A company contracted to manufacture pharmaceutical products.
- PDUFA date
- U.S. FDA approved screening target date. not meant to be approved.
Concept diagram of AI generation13. Source
- Financial Results for FY2025 and FY6 (FY2026-2030) Medium-Term Management Plan Presentation Materials (May 11, 2026). Financial Results for FY2025, Sales revenue of 5DXd ADCs, Receivables for Alliances, Profit Shares, BGT Candidates, Research Bases, TaNeDS, Leading, FY2030 Targets, Cash Allocation, Share Transfer of First Three Co-Healthcare, Patent Expiration, etc. https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf
- Financial Results for the First Quarter of FY2026 (July 2026). Correction of FY2025 financial results, correction of FY2026 financial forecasts, approval of the U.S. and Europe from May to June 2026, resulting from TROPION-Breast02, DS1025. https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_J.pdf
- Supplementary Materials for FY2026 First Quarter Number of employees, capital investment, R&D expenses. https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2026/FY2026Q1_Reference_Data_J.pdf
- Financial Results for FY2025 (May 8, 2026) Review of ADC manufacturing and supply strategy, compensation for loss to CMO, loss of investment in Odawara Plant ADC, and risk of minimum purchase obligations. https://www.daiichisankyo.co.jp/files/investors/library/materials/2026/Revision%20of%20the%20FY2025%20Consolidated%20Financial%20Results%20Forecast%20_J.pdf
- Press Release “Announcement of Global Development and Sales Alliance with AstraZeneca on Trussuzumab Derxekan (DS-8201)” (March 29, 2019) https://www.daiichisankyo.co.jp/media/press_release/detail/index_5623.html
- Press Release Announcement of Global Development and Sales Alliance with AstraZeneca on DS-1062 (July 27, 2020) https://www.daiichisankyo.co.jp/media/press_release/detail/index_5545.html
- Press Release Announcement of Global Development and Sales Alliance with Merck & Co., Inc., Rahway, NJ, USA on DXd-ADC 3 Products (October 20, 2023) https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202310/20231020_J.pdf
- Announcement of Global Development and Sales Alliance with Merck & Co., Inc., Rahway, NJ, USA on MK-6070 (August 7, 2024) https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202408/20240807_J.pdf
- Press Release “Investment of Production Equipment for Antibody Drug Complex (ADC)” (April 27, 2017) https://www.daiichisankyo.co.jp/media/press_release/detail/index_5785.html
- Technical description material "ADC of Dai-ichi Sankyo" (2017) DXd payload, GGFG linker, cysteine binding, GG, comparison of spacer structure and coagulation, and the study of the former Daiichi Pharmaceutical Co., Ltd. https://www.daiichisankyo.co.jp/files/news/ir/pdf/005355/%E3%83%9F%E3%83%BC%E3%83%86%E3%82%A3%E3%83%B3%E3%82%B0%E8%B3%87%E6%96%99.pdf
- US FDA ENHERTU Approval Package (BLA 761139, Dec 20, 2019) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761139Orig1s000Approv.pdf
- Press Release Announcement of Acquisition of Anti-Malignant Tumor Enharts® (March 25, 2020) https://www.daiichisankyo.co.jp/media/press_release/detail/index_5573.html
- Press Release Announcement of Approval of Anti-Malignant Tumors in Japan (December 27, 2024) https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202412/20241227_J.pdf
- Press Release Announcement of DATROWAY® Approval for Sales in the United States (January 20, 2025) https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202501/20250120_J.pdf
- Press Release “Daityrona® Steady Note” (August 2, 2023) https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202307/20230802_J.pdf
- Press Release Announcement of Approval of Partial Amendments to HER2-positive Solid Cancer in Japan (March 23, 2026) https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202603/20260323_J2.pdf
- ClinicalTrials.gov DESTINY-Breast11（NCT05113251）。 https://clinicaltrials.gov/study/NCT05113251
- ClinicalTrials.gov DESTINY-Breast05（NCT04622319）。 https://clinicaltrials.gov/study/NCT04622319
- ClinicalTrials.gov TROPION-Breast02（NCT05374512）。 https://clinicaltrials.gov/study/NCT05374512
- ClinicalTrials.gov IDeate-Lung01（NCT05280470）。 https://clinicaltrials.gov/study/NCT05280470
- "Wish for Cancer Treatment" Researcher's ADC Technologies and Their Future The DX-DX1 of the Daiichi Pharmaceutical Era and the Antibody Research of the Three Co。 Era https://www.daiichisankyo.co.jp/recruit/graduate/special/adc/
- Official website (name and logo) https://www.daiichisankyo.co.jp/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Sales revenue (FY2024, JPY18,863, JPY21,230, JPY2025, JPY2025, JPY2025, JPY15, JPY15, JPY2025, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY15, JPY20, JPY15, JPY15, JPY20, JPY15, JPY20, JPY15, JPY, JPY15, JPY | Facts | Source 1 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| Revised FY2025 financial results (operating income: 2,580 billion yen, net income: 2,797 billion yen) and FY2026 forecast (sales revenue: 2,400 billion yen, operating income: 3,200 billion yen) | Facts | Source 2 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_J.pdf |
| Number of employees: 20, regional breakdowns, capital investments: 354 billion yen, 2026 forecast: 20 billion yen | Facts | Source 3 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2026/FY2026Q1_Reference_Data_J.pdf |
| Sales revenue of 5DXd ADCs: ¥9,253 billion, Enharts: ¥6,984 billion, Datroway: ¥476 billion global product sales | Facts | Source 1 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| Profit share of AstraZeneca 6,851 billion yen, US Merck 6,978 billion yen) | Facts | Source 1 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| Approx. 1 trillion,829 trillion yen of total received consideration is about 3 years of research and development costs, about 43.6% of ADC sales, and about 21.8% of R&D sales | The calculation of this paper | The number of source 1 is calculated and assigned. |
| Enhart tie-up with AstraZeneca (up to $69 billion, halves of profits and costs, manufacturing and supply are the first three) | Facts | Source 5 https://www.daiichisankyo.co.jp/media/press_release/detail/index_5623.html |
| Datroway partnership with AstraZeneca (up to $60 billion) | Facts | Source 6 https://www.daiichisankyo.co.jp/media/press_release/detail/index_5545.html |
| Collaboration of DXd ADC 3 products with Merck in the United States (up to $220 billion, manufacturing and supply of the first three) | Facts | Source 7 https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202310/20231020_J.pdf |
| Addition of MK-6070 (T contract fee of $ 17,000 million, manufacturing is Merck, USA) | Facts | Source 8 https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202408/20240807_J.pdf |
| ADC production equipment investment in 2017 (3 domestic plants, initial investment about 1.5 billion yen) | Facts | Source 9 https://www.daiichisankyo.co.jp/media/press_release/detail/index_5785.html |
| Compensation for loss to CMO, disconnection of investment in Odawara Plant ADC, risk of minimum purchase obligation, new structure of company + CMO | Facts | Source 4 https://www.daiichisankyo.co.jp/files/investors/library/materials/2026/Revision%20of%20the%20FY2025%20Consolidated%20Financial%20Results%20Forecast%20_J.pdf |
| Comparison of DXd payload, GGFG linker, chain-to-chain cysteine binding, GG 7-8, spacer structure and aggregate | Facts | Source10 https://www.daiichisankyo.co.jp/files/news/ir/pdf/005355/%E3%83%9F%E3%83%BC%E3%83%86%E3%82%A3%E3%83%B3%E3%82%B0%E8%B3%87%E6%96%99.pdf |
| Adaptation with Enharts’ U.S. approval (December 20, 2019) | Facts | Source11 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761139Orig1s000Approv.pdf |
| Em Hearts Japan Approval (March 2020, Conditional Early Approval, ILD Warning) | Facts | Source12 https://www.daiichisankyo.co.jp/media/press_release/detail/index_5573.html |
| Japan approval of Datroway (December 2024) and U.S. approval (January 2025) | Facts | Source 13/14 https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202501/20250120_J.pdf |
| Daityrona’s Japan approval (August 2023) | Facts | Source15 https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202307/20230802_J.pdf |
| Japan approval of Enharts’ HER2-positive solid carcinoma (March 2026) | Facts | Source16 https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202603/20260323_J2.pdf |
| U.S. approval (DESTINY-Breast11/05, TROPION-Breast02) and European approval, result of TROPION-Breast02 | Facts | Source 2 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_J.pdf |
| DESTINY-Breast11 pCR improvement 11.2 points and data cutoff, IDeate-Lung01 confirmed ORR 48.2%, HER3-DXd application lowered | Facts | Source 1 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| NCT number, phase, and key evaluation items for each test | Facts | Source 17-20 https://clinicaltrials.gov/study/NCT05113251 |
| Number of IDFS improvements in DESTINY-Breast05, at the time of analysis of TROPION-Breast02 | Undetermined / Future | Not specified in the company documents confirmed in this article. This article does not compensate for numbers https://clinicaltrials.gov/study/NCT04622319 |
| I-DXd’s U.S. Examination Results (Decision End Date October 10, 2026) | Undetermined / Future | Source 1. Undetermined approval https://clinicaltrials.gov/study/NCT05280470 |
| BGT candidates (antibody modified ADC, IO payload, new payload, multi-sphyc antibody, TPD, siRNA) and timing | Facts | Source 1 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| Targets for FY2030, over ¥2 trillion in revenue for cancer area, ¥2.9 trillion in growth investment, patent expiration, etc. | Facts | Source 1 https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| DXd ADC Peak Sales 3 trillion yen or more potential | Undetermined / Future | Source 1. Not a company's and track record https://www.daiichisankyo.co.jp/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_J.pdf |
| Investment amount and production capacity limited to ADC equipment, the company name of CMO and the total amount of minimum purchase obligation, and the translation of modalities for research and development costs | Undetermined / Future | Not specified in the source 1-4. This article does not estimate https://www.daiichisankyo.co.jp/files/investors/library/materials/2026/Revision%20of%20the%20FY2025%20Consolidated%20Financial%20Results%20Forecast%20_J.pdf |
| DX-DX1 is the result of the first pharmaceutical era. DX-DX1 is disco ed after clinical trial | Facts | Source 21 https://www.daiichisankyo.co.jp/recruit/graduate/special/adc/ |
| Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| Read that the next core technology is also on the extension line of ADC | Interpretation of this article from BGT candidate breakdown | |
| Read more than you can develop and sell your own alone | Interpre of this paper from its own independent capabilities policy and the scale of the Profit Share | |
| siRNA・TPD reads to transfer LNP technology to siRNA, which aims at the following of ADC | Interpretation of this draft from the stage and description of the BGT candidate | |
| Risks of the following technical foundations | Interpretation of this article from many of the BGT candidates to be the first phase or earlier |
Last Updated:September 26, 2026/Troy Technical
All the figures in this article are based on the financial statements, financial statements and press releases published by Dai-ichi Sankyo, the U.S. FDA approval document, and the ClinicalTrials.gov。 information. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice.